No Data
No Data
IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
Express News | IGM Biosciences Inc - Expects to End 2024 With Balance of $180 Million in Cash and Investments
Express News | IGM Biosciences - as a Result of Refocusing of Sanofi Collaboration Announced in April, Expects to Recognize FY Collaboration Revenue of $63 Mln
Express News | IGM Biosciences Inc - Expects Full Year 2024 Gaap Operating Expenses of $210 Million to $220 Million
No Data
Pinchie McPincher : theye just announced updated formluation of fostrox
Pinchie McPincher : just announced updated formulation of fostrox , criticsal to support planned study with accelrated approval intent in 2nd lineHCC